【摘要】 药物治疗是稳定期慢性阻塞性肺疾病的重要干预措施，有效的药物干预可显著改善慢性阻塞性肺疾病患者的临床症状和生活质量，还能降低急性加重风险。但是目前世界范围内面临着经济发展欠均衡、医疗投入不足、药物费用偏高等困难，导致慢性阻塞性肺疾病稳定期治疗药物的可及性存在挑战，如慢性阻塞性肺疾病药物尤其是吸入性药物配备不足、不同等级医疗机构之间慢性阻塞性肺疾病药物配置差异大等一系列问题，进而影响慢性阻塞性肺疾病的规范化治疗。本文就稳定期慢性阻塞性肺疾病治疗药物可及性的国内外研究进展作一述评，拟为慢性阻塞性肺疾病的管理提供更多临床证据。更多还原

【Abstract】 Drug therapy is an important intervention for stable chronic obstructive pulmonary disease(COPD). Effective drug therapy can significantly improve the clinical symptoms and quality of life, and reduce the risk of acute exacerbation. However, the world is currently facing difficulties such as uneven economic development, insufficient investment inmedical care, and high drug costs, which pose challenges to the availability of drugs for COPD. There are a series of problems, such as in sufficient supply of drugs for COPD, especially inhaled drugs, and significant differences in drug configuration among different levels of medical institutions, which in turn affect the standardized treatment. This article systematically summarized the research progress on the availability of drugs for the treatment of stable COPD at home and abroad, attempting to provide more clinic evidence for the management of COPD.更多还原